PBMWW - Psyence Biomedical Ltd.
NYSE
$0.03
$-0.00 (-7.03%)
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
PBMWW Key Statistics
Market Cap
$0.00M
Employees
12
How PBMWW Compares to Peers
P/E Rank
N/A
of 1
Margin Rank
N/A
of 1
Growth Rank
N/A
of 1
Size Rank
N/A
of 1
Psyence Biomedical Ltd. Company Information
- Headquarters
- 121 Richmond Street West, Toronto, ON, Canada, M5H2K1, undefined
- Website
- www.psyencebiomed.com